vs

Side-by-side financial comparison of Axos Financial, Inc. (AX) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

Axos Financial, Inc. is the larger business by last-quarter revenue ($392.2M vs $321.1M, roughly 1.2× MADRIGAL PHARMACEUTICALS, INC.). Axos Financial, Inc. runs the higher net margin — 31.8% vs -18.2%, a 50.0% gap on every dollar of revenue.

Axos Financial is an American bank holding company based in Las Vegas, Nevada and is the parent of Axos Bank, a direct bank. It also offers registered investment adviser services and an electronic trading platform.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

AX vs MDGL — Head-to-Head

Bigger by revenue
AX
AX
1.2× larger
AX
$392.2M
$321.1M
MDGL
Higher net margin
AX
AX
50.0% more per $
AX
31.8%
-18.2%
MDGL

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
AX
AX
MDGL
MDGL
Revenue
$392.2M
$321.1M
Net Profit
$124.7M
$-58.6M
Gross Margin
Operating Margin
-18.6%
Net Margin
31.8%
-18.2%
Revenue YoY
210.8%
Net Profit YoY
18.5%
1.4%
EPS (diluted)
$2.15
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AX
AX
MDGL
MDGL
Q1 26
$392.2M
Q4 25
$385.1M
$321.1M
Q3 25
$323.4M
$287.3M
Q2 25
$321.4M
$212.8M
Q1 25
$308.8M
$137.3M
Q4 24
$307.9M
$103.3M
Q3 24
$320.7M
$62.2M
Q2 24
$290.9M
Net Profit
AX
AX
MDGL
MDGL
Q1 26
$124.7M
Q4 25
$128.4M
$-58.6M
Q3 25
$112.4M
$-114.2M
Q2 25
$110.7M
$-42.3M
Q1 25
$105.2M
$-73.2M
Q4 24
$104.7M
$-59.4M
Q3 24
$112.3M
$-107.0M
Q2 24
$104.9M
Gross Margin
AX
AX
MDGL
MDGL
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Operating Margin
AX
AX
MDGL
MDGL
Q1 26
Q4 25
45.6%
-18.6%
Q3 25
46.3%
-39.7%
Q2 25
48.5%
-22.2%
Q1 25
47.9%
-57.8%
Q4 24
48.8%
-64.8%
Q3 24
49.6%
-187.1%
Q2 24
49.6%
Net Margin
AX
AX
MDGL
MDGL
Q1 26
31.8%
Q4 25
33.3%
-18.2%
Q3 25
34.7%
-39.8%
Q2 25
34.4%
-19.9%
Q1 25
34.1%
-53.4%
Q4 24
34.0%
-57.5%
Q3 24
35.0%
-172.0%
Q2 24
36.0%
EPS (diluted)
AX
AX
MDGL
MDGL
Q1 26
$2.15
Q4 25
$2.22
$-2.55
Q3 25
$1.94
$-5.08
Q2 25
$1.89
$-1.90
Q1 25
$1.81
$-3.32
Q4 24
$1.80
$-2.50
Q3 24
$1.93
$-4.92
Q2 24
$1.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AX
AX
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$3.1B
$602.7M
Total Assets
$29.2B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AX
AX
MDGL
MDGL
Q1 26
Q4 25
$1.0B
$198.7M
Q3 25
$2.6B
$295.7M
Q2 25
$1.9B
$186.2M
Q1 25
$2.0B
$183.6M
Q4 24
$2.4B
$100.0M
Q3 24
$2.6B
$232.7M
Q2 24
$2.0B
Total Debt
AX
AX
MDGL
MDGL
Q1 26
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$312.7M
$118.4M
Q1 25
$377.4M
$118.0M
Q4 24
$358.7M
$117.6M
Q3 24
$313.5M
$117.1M
Q2 24
$325.7M
Stockholders' Equity
AX
AX
MDGL
MDGL
Q1 26
$3.1B
Q4 25
$2.9B
$602.7M
Q3 25
$2.8B
$625.7M
Q2 25
$2.7B
$696.0M
Q1 25
$2.6B
$710.6M
Q4 24
$2.5B
$754.4M
Q3 24
$2.4B
$777.2M
Q2 24
$2.3B
Total Assets
AX
AX
MDGL
MDGL
Q1 26
$29.2B
Q4 25
$28.2B
$1.3B
Q3 25
$27.4B
$1.4B
Q2 25
$24.8B
$1.0B
Q1 25
$24.0B
$996.6M
Q4 24
$23.7B
$1.0B
Q3 24
$23.6B
$1.1B
Q2 24
$22.9B
Debt / Equity
AX
AX
MDGL
MDGL
Q1 26
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.12×
0.17×
Q1 25
0.14×
0.17×
Q4 24
0.14×
0.16×
Q3 24
0.13×
0.15×
Q2 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AX
AX
MDGL
MDGL
Operating Cash FlowLast quarter
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AX
AX
MDGL
MDGL
Q1 26
Q4 25
$104.1M
$-133.5M
Q3 25
$118.4M
$79.8M
Q2 25
$490.3M
$-47.1M
Q1 25
$73.7M
$-88.9M
Q4 24
$162.5M
$-104.5M
Q3 24
$70.8M
$-67.0M
Q2 24
$305.5M
Free Cash Flow
AX
AX
MDGL
MDGL
Q1 26
Q4 25
$85.4M
$-133.8M
Q3 25
$109.3M
$79.0M
Q2 25
$436.1M
Q1 25
$65.1M
Q4 24
$156.4M
$-104.7M
Q3 24
$53.0M
$-67.8M
Q2 24
$269.5M
FCF Margin
AX
AX
MDGL
MDGL
Q1 26
Q4 25
22.2%
-41.7%
Q3 25
33.8%
27.5%
Q2 25
135.7%
Q1 25
21.1%
Q4 24
50.8%
-101.3%
Q3 24
16.5%
-109.0%
Q2 24
92.6%
Capex Intensity
AX
AX
MDGL
MDGL
Q1 26
Q4 25
4.9%
0.1%
Q3 25
2.8%
0.3%
Q2 25
16.9%
0.0%
Q1 25
2.8%
0.0%
Q4 24
2.0%
0.2%
Q3 24
5.5%
1.3%
Q2 24
12.4%
Cash Conversion
AX
AX
MDGL
MDGL
Q1 26
Q4 25
0.81×
Q3 25
1.05×
Q2 25
4.43×
Q1 25
0.70×
Q4 24
1.55×
Q3 24
0.63×
Q2 24
2.91×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AX
AX

Net Interest Income$306.3M78%
Noninterest Income$86.0M22%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons